Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Abstract Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line mo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-09-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-021-01161-8 |
| _version_ | 1819239452603580416 |
|---|---|
| author | Wenjing Qian Mingfang Zhao Ruoyu Wang Heming Li |
| author_facet | Wenjing Qian Mingfang Zhao Ruoyu Wang Heming Li |
| author_sort | Wenjing Qian |
| collection | DOAJ |
| description | Abstract Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line monotherapies in certain tumor types. However, the efficacy of anti-PD-1/PD-L1 mAbs is still limited due to toxic side effects and de novo or adaptive resistance. Moreover, other immune checkpoint target and biomarkers for therapeutic response prediction are still lacking; as a biomarker, the PD-L1 (CD274, B7-H1) expression level is not as accurate as required. Hence, it is necessary to seek more representative predictive molecules and potential target molecules for immune checkpoint therapy. Fibrinogen-like protein 1 (FGL1) is a proliferation- and metabolism-related protein secreted by the liver. Multiple studies have confirmed that FGL1 is a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3), emphasizing the potential of targeting FGL1/LAG3 as the next generation of immune checkpoint therapy. In this review, we summarize the substantial regulation mechanisms of FGL1 in physiological and pathological conditions, especially tumor epithelial to mesenchymal transition, immune escape and immune checkpoint blockade resistance, to provide insights for targeting FGL1 in cancer treatment. |
| first_indexed | 2024-12-23T13:52:21Z |
| format | Article |
| id | doaj.art-bde087ed0c634ef7af10c3e368eb935b |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-23T13:52:21Z |
| publishDate | 2021-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-bde087ed0c634ef7af10c3e368eb935b2022-12-21T17:44:33ZengBMCJournal of Hematology & Oncology1756-87222021-09-0114111710.1186/s13045-021-01161-8Fibrinogen-like protein 1 (FGL1): the next immune checkpoint targetWenjing Qian0Mingfang Zhao1Ruoyu Wang2Heming Li3Department of Oncology, Affiliated Zhongshan Hospital of Dalian UniversityDepartment of Medical Oncology, the First Hospital of China Medical UniversityDepartment of Oncology, Affiliated Zhongshan Hospital of Dalian UniversityDepartment of Medical Oncology, the First Hospital of China Medical UniversityAbstract Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line monotherapies in certain tumor types. However, the efficacy of anti-PD-1/PD-L1 mAbs is still limited due to toxic side effects and de novo or adaptive resistance. Moreover, other immune checkpoint target and biomarkers for therapeutic response prediction are still lacking; as a biomarker, the PD-L1 (CD274, B7-H1) expression level is not as accurate as required. Hence, it is necessary to seek more representative predictive molecules and potential target molecules for immune checkpoint therapy. Fibrinogen-like protein 1 (FGL1) is a proliferation- and metabolism-related protein secreted by the liver. Multiple studies have confirmed that FGL1 is a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3), emphasizing the potential of targeting FGL1/LAG3 as the next generation of immune checkpoint therapy. In this review, we summarize the substantial regulation mechanisms of FGL1 in physiological and pathological conditions, especially tumor epithelial to mesenchymal transition, immune escape and immune checkpoint blockade resistance, to provide insights for targeting FGL1 in cancer treatment.https://doi.org/10.1186/s13045-021-01161-8FGL1LAG-3BiomarkerImmune resistanceImmune checkpoint blockade |
| spellingShingle | Wenjing Qian Mingfang Zhao Ruoyu Wang Heming Li Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target Journal of Hematology & Oncology FGL1 LAG-3 Biomarker Immune resistance Immune checkpoint blockade |
| title | Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target |
| title_full | Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target |
| title_fullStr | Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target |
| title_full_unstemmed | Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target |
| title_short | Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target |
| title_sort | fibrinogen like protein 1 fgl1 the next immune checkpoint target |
| topic | FGL1 LAG-3 Biomarker Immune resistance Immune checkpoint blockade |
| url | https://doi.org/10.1186/s13045-021-01161-8 |
| work_keys_str_mv | AT wenjingqian fibrinogenlikeprotein1fgl1thenextimmunecheckpointtarget AT mingfangzhao fibrinogenlikeprotein1fgl1thenextimmunecheckpointtarget AT ruoyuwang fibrinogenlikeprotein1fgl1thenextimmunecheckpointtarget AT hemingli fibrinogenlikeprotein1fgl1thenextimmunecheckpointtarget |